ImmunoGen, Inc.
$919.6K 430 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals, Inc. reported $918,153.45 across General Payments, Research, and Ownership to 3,940 physicians and teaching hospitals across 4,019 transactions.
- $918.2K Above-median payer
- All-tracks total
- 4,019 Top quartile volume
- Transactions
- 3,940 Top quartile reach
- Recipients
- −$96.1K
- General Payments vs PY2023
Cumberland Pharmaceuticals, Inc. reported $918,153.45 across all CMS Open Payments tracks (General + Research + Ownership) to 3,940 physicians and teaching hospitals in Program Year 2024 - ranking #642 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $341,441.45, averaging $233.03 per recipient.
How Cumberland Pharmaceuticals, Inc.'s $918.2K all-tracks total breaks down
Cumberland Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
40/100
Total payments
F
18/100
Transaction volume
F
39/100
Physician reach
F
40/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cumberland-pharmaceuticals-inc Cumberland Pharmaceuticals, Inc.
$918.2K · #642/1,925 · 0.0% industry · PY2024
- TOT $918.2K
- RANK #642
- SHARE 0.0%
- TXN 4,019
- RCP 3,940
- CAT 5
- GEN $341.4K
- ΔGEN −$96.1K
- TOP1 29.1%
- PY 2024
Volume peers
Nearest volume peer: ImmunoGen, Inc. ($919.6K)
Cumberland Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cumberland Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $96.1K (−22.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CUMBERLAND PHARMACEUTICALS, INC.PY2023: CUMBERLAND PHARMACEUTICALS, INC.PY2024: Cumberland Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $437,566.34
- PY2024
- $341,441.45
What the Data Shows for Cumberland Pharmaceuticals, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Cumberland Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 5-category general-payment breakdown below at $177.3K (51.9% of General Payments, 33 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Cumberland Pharmaceuticals, Inc. made 5 types of general payments. "Consulting Fee" is the largest category at $177.3K, 51.9% of General Payments.
Cumberland Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Consulting Fee (51.9%), Compensation for Services Other Than Consulting (23.6%), and Food and Beverage (23.4%). The remaining 2 categories make up 1.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Cumberland Pharmaceuticals, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $177.3K | 33 | 51.9% |
| Compensation for Services Other Than Consulting | $80.7K | 75 | 23.6% |
| Food and Beverage | $79.8K | 3,727 | 23.4% |
| Travel and Lodging | $3.4K | 6 | 1.0% |
| Education | $364.43 | 99 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $183,629.64 (53.8%) of $341,441.45 in this company's General Payments records across 2,544 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cumberland Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Gordon Bernard
$99,500.00 across 10 reported transactions
- 2
Todd Rice
$36,152.98 across 11 reported transactions
- 3
Vatsala Sastry
$21,100.82 across 13 reported transactions
- 4
Michael Lew
$13,750.84 across 11 reported transactions
- 5
Mohamed Erritouni
$13,125.00 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cumberland Pharmaceuticals, Inc. ranks #642 of 1,925 by total payments (top 33% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #998 of 1,838 by HHI (bottom 46% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- GM Pharmaceuticals, Inc. : $1.8K total payments, HHI 1093
- Flower Orthopedics Coporation : $381.4K total payments, HHI 1092
- Metric Medical Devices, Inc. : $10.9K total payments, HHI 1090
- CurvaFix, Inc. : $140.6K total payments, HHI 1090
- SpringWorks Therapeutics, Inc. : $1.4M total payments, HHI 1087
- Ion Beam Applications S.A. : $32.3K total payments, HHI 1083
- Cumberland Pharmaceuticals, Inc. (this company) : $341.4K total payments, HHI 1083
- Cook Incorporated : $6.0M total payments, HHI 1081
- Grifols Shared Services North America, Inc. : $105.0K total payments, HHI 1080
- BioCryst Pharmaceuticals, Inc. : $326.1K total payments, HHI 1076
- Vektor Medical Inc. : $86.8K total payments, HHI 1068
- Magenta Medical Inc : $47.9K total payments, HHI 1068
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cumberland Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cumberland Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cumberland Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Zealand Pharma A/S
$919.9K 108 recipients
Compare payment profiles
Aesculap, Inc.
$921.5K 705 recipients
Compare payment profiles
Access Vascular Inc
$914.0K 47 recipients
Compare payment profiles
Spineology Inc.
$923.8K 1,284 recipients
Compare payment profiles
Rapid Medical Ltd
$930.1K 670 recipients
Compare payment profiles
Put this to use
Cumberland Pharmaceuticals, Inc. ranks #642 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Cumberland Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Cumberland Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.